Seaport Therapeutics is a biotechnology company focused on developing innovative therapies using its proprietary Glyph TM technology. The company aims to address unmet medical needs through advanced clinical and preclinical development of its product candidates. Their business model revolves around the commercialization of these therapies following successful regulatory approvals.
Per S-1 disclosure; % may not sum to 100% when ownership is nested, multi-class, or reported on different bases.
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | Not provided | Not provided |
| Adjusted Net Loss | -$74.9M | -$46.9M |
Based on price range midpoint and most recent fiscal year data.
The company operates in the biotechnology sector, competing with established firms such as PureTech Health and other biotechnology companies involved in similar therapeutic areas. The industry is characterized by lengthy and costly clinical development processes.
Proceeds from the IPO are expected to be utilized for advancing the company's clinical trials and supporting the commercialization of its product candidates.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.